CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors

Jiawan Wang, Ana Calizo, Lindy Zhang, James C. Pino, Yang Lyu, Kai Pollard, Xiaochun Zhang, Alex T. Larsson, Eric Conniff, Nicolas J. Llosa, David K. Wood, David A. Largaespada, Susan E. Moody, Sara J. Gosline, Angela C. Hirbe, Christine A. Pratilas

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas with limited treatment options, and new effective therapeutic strategies are desperately needed. We observe antiproliferative potency of genetic depletion of PTPN11 or pharmacological inhibition using the SHP2 inhibitor (SHP2i) TNO155. Our studies into the signaling response to SHP2i reveal that resistance to TNO155 is partially mediated by reduced RB function, and we therefore test the addition of a CDK4/6 inhibitor (CDK4/6i) to enhance RB activity and improve TNO155 efficacy. In combination, TNO155 attenuates the adaptive response to CDK4/6i, potentiates its antiproliferative effects, and converges on enhancement of RB activity, with greater suppression of cell cycle and inhibitor-of-apoptosis proteins, leading to deeper and more durable antitumor activity in in vitro and in vivo patient-derived models of MPNST, relative to either single agent. Overall, our study provides timely evidence to support the clinical advancement of this combination strategy in patients with MPNST and other tumors driven by loss of NF1.

Original languageEnglish
Article numberadg8876
JournalScience Advances
Volume9
Issue number47
DOIs
StatePublished - Nov 2023

Fingerprint

Dive into the research topics of 'CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors'. Together they form a unique fingerprint.

Cite this